KEYNOTE-189: Chemotherapy Plus Immunotherapy Now a Viable Option for PD-L1 Low Expression Non-Small Cell … – Medscape
Medscape |
KEYNOTE-189: Chemotherapy Plus Immunotherapy Now a Viable Option for PD-L1 Low Expression Non-Small Cell …
Medscape The hazard ratio (HR) for OS was 0.49 with a difference at 1 year in OS of about 20%—from over 49% in the control arm to nearly 70% in the chemo-immunotherapy arm. Clearly, this was a very significant result. Leena Gandhi, who presented at AACR and … |
